CTOs on the Move


 
Absci is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. We built our Integrated Drug Creation™ Platform to accelerate discovery of novel biotherapeutic drug candidates and generation of the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to develop new protein-based drugs, including those that may be impossible to make with other technologies. Our goal is to enable the creation of better medicines by Translating Ideas into Drugs.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.absci.com
  • 18105 SouthEast Mill Plain Boulevard
    Vancouver, WA USA 98683
  • Phone: 360.949.1041

Executives

Name Title Contact Details
Andreas Busch
Chief Innovation Officer Profile

Similar Companies

Research and Diagnostic Systems

Research and Diagnostic Systems is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sapience Therapeutics

Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme (GBM), which is the most severe and deadly form of brain cancer.

Tides Medical

Tides Medical is a privately funded medical technology firm located in Lafayette, LA, is a leader in the growing market for amniotic membrane technology. Our focus is on providing patients with safe, effective therapies, physicians with reliable produc...

Greffex

Greffex™ is a privately held, multi-national company, headquartered in Aurora, Colorado. Established in 1999, Greffex has developed a novel genetic platform for the development and production of vaccines. Our proprietary GREVAX™ Universal Platform delivers vaccines in a faster, more affordable and more efficient manner. Once a pathogen has been identified, Greffex`s team designs and produces a GREVAX™ vaccine in as little as 4 weeks. The state-of-the-art flexibility of the GREVAX™ Universal Platform makes it the ideal delivery vehicle for vaccines against a wide variety of infectious disease, including but not limited to Pandemic Influenza strains, Anthrax and Dengue Fever, as well as Malaria, Hepatitis C, Respiratory Syncytial Virus (RSV), Ebola, HPV, Plague, Tuberculosis and a host of other vaccine candidates.

RetinaPharma Technologies

RetinaPharma Technologies is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.